Key result
Intravenous FCM dominates placebo for HF iron deficiency, saving Italy an estimated ~97 million Euros annually.
Why the study?
The cost-effectiveness and national healthcare budget impact of intravenous ferric carboxymaltose versus placebo for iron deficiency in chronic heart failure in Italy needed evaluation.
Is intravenous ferric carboxymaltose cost-effective compared to placebo for managing iron deficiency in patients with chronic heart failure in Italy?
Is intravenous ferric carboxymaltose cost-effective compared to placebo for managing iron deficiency in patients with chronic heart failure in Italy?
Intravenous ferric carboxymaltose is a cost-saving strategy for treating iron deficiency in chronic heart failure patients in Italy, potentially saving 20-97 million Euros annually.
May support modeled cost savings with ferric carboxymaltose in Italian heart failure care; hypothesis-generating pending real-world validation.
Aim: To evaluate the cost–effectiveness of intravenous ferric carboxymaltose (FCM) versus placebo for the management of iron deficiency in patients with chronic heart failure in the Italian healthcare system and to estimate its impact on the national healthcare budget. Materials & methods: A Markov model was developed to project costs and health outcomes over 1 year, based on data from literature. Healthcare resources consumption was derived from an e-survey administered to clinicians. Costs were obtained from official tariffs. Results: Treatment with FCM represents a dominant strategy compared with placebo, leading to national budget annual savings of 20–97 million Euros, according to different increasing utilization rates. Conclusion: FCM is a cost-saving option for the treatment of chronic heart failure patients with iron deficiency in Italy.
No takes yet. Share an insight, caveat, or question.
Rognoni et al. (2019) studied Chronic heart failure with iron deficiency. Intravenous ferric carboxymaltose (FCM) vs. Placebo was evaluated on Cost-effectiveness and national budget annual savings (20-97 million Euros annual savings). Intravenous ferric carboxymaltose was a dominant strategy compared with placebo for managing iron deficiency in chronic heart failure, leading to estimated national budget annual savings of 20–97 million Euros in Italy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: